Vision Marine Stock (NASDAQ:VMAR), Trade Ideas

Vision Marine

Vision Marine Technologies Inc is in the business of designing and manufacturing electric outboard powertrain systems, power boats, and related technology and the renting of electric boats. The different models of the powerboats and electric boats manufactured by the company includes, Bruce 22, Fantail 217, Volt 180 and others. The company operates in two reportable business segments; Sale of electric boats and Rental of electric boats. The majority of the revenue for the company is generated from its Rental of electric boats segment. Geographically, the company generates revenue from its business in Canada, USA and other countries. A substantial portion of the overall revenue is generated from its business in USA.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

APTO

AREB

CISS

CVKD

IFRX

Intelligent Bio Solutions Inc. - Common Stock

INBS

INTC

JAGX

KLAC

ONCO

REVB

TCBP

TELL

VMAR

WLGS

YIBO

Shares of  Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale.

Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Long Ideas

DBGI

FFIE

MBLY

UCAR

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.

Top 5 Consumer Stocks That May Rocket Higher In Q1

Intraday Update

ABSI

ADAG

AGAE

AGFY

ALLY

ASTS

AXDX

AZTR

BCDA

BFRG

CELH

CHGG

CRGE

DTSS

ESPR

EWTX

GOOG

GOOGL

IRBT

KAMN

MESA

MESO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NAMS

NKTX

ORGS

PCSA

PRTG

RNAZ

SAVE

SHPH

SILK

SMCI

SOAR

WRLD

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session.

TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.

TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Vision Marine Technologies Inc. - Common Shares

Vision Marine Technologies Inc

<p>Citigroup  analyst Ygal Arounian   maintains Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) with a Neutral and lowers the price target from $74 to $62.</p>


Price Target

Analyst Ratings

Citigroup Maintains Neutral on Ziff Davis, Lowers Price Target to $62

<p>Citigroup  analyst Jon Tower   maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Neutral and raises the price target from $25 to $28.</p>


Citigroup Maintains Neutral on Sweetgreen, Raises Price Target to $28

<p>Citigroup  analyst David Hoang   maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.</p>


XENE

Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

<p>Citigroup  analyst Jason Bazinet   maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $80 to $98.</p>


Citigroup Maintains Buy on AppLovin, Raises Price Target to $98

<p>Citigroup  analyst David Lebowitz   maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Neutral and lowers the price target from $31 to $29.</p>


NTLA

Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29

<p>Citigroup  analyst Drew Foster   maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and lowers the price target from $798 to $767.</p>


HUBS

Citigroup Maintains Buy on HubSpot, Lowers Price Target to $767

<p>Citigroup  analyst George Kurosawa   maintains SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and raises the price target from $213 to $222.</p>


SPSC

Citigroup Maintains Buy on SPS Commerce, Raises Price Target to $222

<p>CORRECTION: &nbsp;Benchmark analyst Cody Acree reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $40 to $50. - Price Target Change updated</p>


Reiteration

TSEM

CORRECTION: Benchmark Reiterates Buy on Tower Semiconductor, Raises Price Target to $50 – Price Target Change updated

<p>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3.53) by 42.78 percent. This is a 51.9 percent increase over losses of $(4.20) per share from the same period last year.</p>


Earnings

Earnings Beats

MBRX

Moleculin Biotech Q1 EPS $(2.02) Beats $(3.53) Estimate

<p><strong>Production, Prices and Revenue:</strong>&nbsp;&nbsp; Production for the first quarter of 2024 was 35.1 MBoe/d compared with 34.1 MBoe/d for the fourth quarter of 2023 and 32.5 MBoe/d for the corresponding period in 2023. The increase in production compared to the fourth quarter of 2023 was primarily driven by the inclusion of the Cox acquisition, which closed in January 2024 and was partially offset by natural decline. First quarter 2024 production was comprised of 15.4 thousand barrels per day ("MBbl/d") of oil (44%), 3.8 MBbl/d of natural gas liquids ("NGLs") (11%), and 96.0 million cubic feet per day ("MMcf/d") of natural gas (45%). Production in the second quarter of 2024 will be negatively impacted by planned maintenance which required shut-ins of select fields and is reflected in second quarter guidance.</p>
<p>&nbsp;</p>
<p><strong>Second Quarter and Full Year 2024 Production and Expense Guidance</strong></p>
<p>The guidance for the second quarter and full year 2024 in the table below represents the Company's current expectations. Please refer to the section entitled "Forward-Looking and Cautionary Statements" below for risk factors that could impact guidance.</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>Production</td>
<td>Second Quarter 2024</td>
<td>Full Year 2024</td>
</tr>
<tr>
<td>Oil (MBbl)</td>
<td>1,225 – 1,400</td>
<td>5,100 – 5,800</td>
</tr>
<tr>
<td>NGLs (MBbl)</td>
<td>280 – 315</td>
<td>1,150 – 1,375</td>
</tr>
<tr>
<td>Natural gas (MMcf)</td>
<td>8,800 – 10,060</td>
<td>37,000 – 44,500</td>
</tr>
<tr>
<td>Total equivalents (MBoe)</td>
<td>2,972 – 3,392</td>
<td>12,417 – 14,592</td>
</tr>
<tr>
<td>Average daily equivalents (MBoe/d)</td>
<td>32.7 – 37.3</td>
<td>33.9 – 39.9</td>
</tr>
<tr>
<td>Expenses</td>
<td>Second Quarter 2024</td>
<td>Full Year 2024</td>
</tr>
<tr>
<td>Lease operating expense ($MM)</td>
<td>83.0 – 92.0</td>
<td>295.0 – 332.0</td>
</tr>
<tr>
<td>Gathering, transportation &amp; production taxes ($MM)</td>
<td>8.1 – 8.9</td>
<td>34.5 – 39.0</td>
</tr>
<tr>
<td>General &amp; administrative – cash ($MM)</td>
<td>13.7 – 15.1</td>
<td>59.0 – 66.5</td>
</tr>
<tr>
<td>General &amp; administrative – non-cash ($MM)</td>
<td>2.9 – 3.3</td>
<td>12.5 – 14.0</td>
</tr>
<tr>
<td>DD&amp;A ($ per Boe)</td>
<td>11.4 – 12.9</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>W&amp;T expects substantially all taxes in 2024 to be deferred.&nbsp;</p>


Guidance

W&T Offshore Says Production In Q2 2024 Will Be Negatively Impacted By Planned Maintenance Which Required Shut-Ins Of Select Fields And Is Reflected In Q2 Guidance

<p>W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year.  The company reported quarterly sales of $140.79 million which beat the analyst consensus estimate of $139.56 million by 0.88 percent.  This is a 6.88 percent increase over sales of $131.72 million the same period last year.</p>


W&T Offshore Q1 Adj $(0.05) Beats $(0.06) Estimate, Sales $140.79M Beat $139.56M Estimate

<p>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, today announced that on May 7, 2024, it received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement.</p>


EVAX

Evaxion Received A Letter From The Nasdaq Listing Qualifications Department Notifying That It Is Not Currently In Compliance With The Minimum Stockholders' Equity Requirement

<p>Benchmark  analyst Cody Acree   reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $40 to $50.</p>


CORRECTION: Benchmark Reiterates Buy on Tower Semiconductor, Raises Price Target to $50

<p>Zepp Health Corporation ("Zepp" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is below compliance standards due to the trading price of Zepp's American depositary shares (the "ADSs").</p>


ZEPP

Zepp Health Gets NYSE Non-Compliance Letter Notifying The Co That It Is Below Compliance Standards Due To The Trading Price Of It's ADSs

<p>In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $50.0, a high estimate of $80.00, and a low estimate of $28.00. Surpassing the previous average price target of $30.00, the current average has increased by 66.67%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374871_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Schwartz</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AnaptysBio's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AnaptysBio analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know AnaptysBio Better</h2>
<p>AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).</p>
<h3>AnaptysBio: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, AnaptysBio showcased positive performance, achieving a revenue growth rate of <strong>32.27%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> AnaptysBio's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-468.75%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AnaptysBio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-40.49%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> AnaptysBio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.98%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> AnaptysBio's debt-to-equity ratio surpasses industry norms, standing at <strong>0.2</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ANAB

The Analyst Landscape: 7 Takes On AnaptysBio

<p>During the last three months, 5 analysts shared their evaluations of RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $54.4, with a high estimate of $60.00 and a low estimate of $48.00. This current average reflects an increase of 14.53% from the previous average price target of $47.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374856_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to RadNet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of RadNet compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of RadNet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of RadNet's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on RadNet analyst ratings.</strong></a></p>
<h2>Delving into RadNet's Background</h2>
<p>RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.</p>
<h3>RadNet's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> RadNet displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>9.51%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> RadNet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.44%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-0.3%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> RadNet's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.07%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> RadNet's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.36</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RDNT

Peeling Back The Layers: Exploring RadNet Through Analyst Insights

<p>Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $124.11, a high estimate of $138.00, and a low estimate of $105.00. Marking an increase of 10.81%, the current average surpasses the previous average price target of $112.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374845_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Emerson Electric among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$116.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Nicole Deblase</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$133.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Philip Buller</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Emerson Electric. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Emerson Electric compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Emerson Electric's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Emerson Electric's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EMR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Emerson Electric analyst ratings.</strong></a></p>
<h2>Get to Know Emerson Electric Better</h2>
<p>Emerson Electric sells automation equipment and services under two segments: intelligent devices and software control. Within software and control, it also holds a majority interest in AspenTech, an industrial software business, and owns a test and measurement business that was formerly National Instruments. Intelligent devices also holds Emerson's tools business, which boasts several household brands, like Ridgid. Emerson's automation business is most known for its process manufacturing solutions, which consists of measurement and analytical instrumentation, as well as control valves and actuators, among other products and services. Nearly half of the firm's geographic sales come from the Americas.</p>
<h3>Key Indicators: Emerson Electric's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Emerson Electric's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.51%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Emerson Electric's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.45%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Emerson Electric's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.41%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Emerson Electric's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.08%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Emerson Electric's debt-to-equity ratio is below the industry average at <strong>0.55</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Emerson Electric Through The Eyes Of 9 Analysts

<p>Across the recent three months, 7 analysts have shared their insights on FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.71, along with a high estimate of $21.00 and a low estimate of $18.00. Highlighting a 3.85% decrease, the current average has fallen from the previous average price target of $20.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374834_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive FS KKR Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryce Rowe</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ryan Lynch</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Melissa Wedel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Erik Zwick</td>
<td>Hovde Group</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to FS KKR Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FS KKR Capital compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for FS KKR Capital's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into FS KKR Capital's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FSK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on FS KKR Capital analyst ratings.</strong></a></p>
<h2>Delving into FS KKR Capital's Background</h2>
<p>FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.</p>
<h3>FS KKR Capital's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> FS KKR Capital displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>46.88%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> FS KKR Capital's net margin excels beyond industry benchmarks, reaching <strong>63.83%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.3%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> FS KKR Capital's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.58%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.2</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring FS KKR Capital Through Analyst Insights

<p>10 analysts have expressed a variety of opinions on Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $252.3, a high estimate of $282.00, and a low estimate of $190.00. This upward trend is evident, with the current average reflecting a 14.33% increase from the previous average price target of $220.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374826_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Duolingo by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Mario Lu</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$230.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$267.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Bryan Smilek</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$270.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$241.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Mario Lu</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$243.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$282.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Duolingo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Duolingo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Duolingo's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Duolingo's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DUOL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Duolingo analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Duolingo</h2>
<p>Duolingo Inc is a technology company that develops mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include The Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has three predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test.</p>
<h3>Understanding the Numbers: Duolingo's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Duolingo displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.97%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Duolingo's net margin excels beyond industry benchmarks, reaching <strong>16.09%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Duolingo's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.95%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.67%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.08</strong>, Duolingo adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DUOL

Demystifying Duolingo: Insights From 10 Analyst Reviews

<p>In the latest quarter, 4 analysts provided ratings for Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $45.75, along with a high estimate of $54.00 and a low estimate of $40.00. This current average reflects an increase of 1.67% from the previous average price target of $45.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374817_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Baxter Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Baxter Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Baxter Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Baxter Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Baxter Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BAX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Baxter Intl analyst ratings.</strong></a></p>
<h2>Get to Know Baxter Intl Better</h2>
<p>Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.</p>
<h3>Baxter Intl: Delving into Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Baxter Intl showcased positive performance, achieving a revenue growth rate of <strong>2.25%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>1.03%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Baxter Intl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.45%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.13%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Baxter Intl's debt-to-equity ratio surpasses industry norms, standing at <strong>1.73</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Baxter Intl Through 4 Analysts

Vision Marine Technologies, Inc. (VMAR) has released an update. Vision Marine Technologies, in partnership with McLaren Engineering, has set a new ...

Vision Marine Sets Benchmark in Electric Boating

Vision Marine Technologies, Inc. (VMAR) has released an update. Vision Marine Technologies Inc. reports a decrease in total assets from $24.05 mill...

Vision Marine's Financial Health Deteriorates

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Vision Marine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vmar-stock-quote/"><strong>VMAR</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Vision Marine reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -25 cents.</li><li>The company reported revenue of $542,197.</li><li>This was 78.74% worse than the analyst estimate for revenue of $2.55 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/vmar-stock-earnings-vision-marine-for-q2-of-2024/">VMAR Stock Earnings: Vision Marine Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

VMAR Stock Earnings: Vision Marine Misses EPS, Misses Revenue for Q2 2024

Warning: VMAR is at high risk of performing badly

Vision Marine Technologies, Inc. (VMAR) has released an update. Vision Marine Technologies Inc. has filed for a patent on a new encryption technolo...

Vision Marine Elevates Marine Security with Encryption Patent

Vision Marine Technologies, Inc. (VMAR) has released an update. Vision Marine Technologies, Inc., a leader in electric marine propulsion, has filed...

Vision Marine Innovates with E-Motion™ Encryption Patent

Vision Marine Technologies, Inc. (VMAR) has released an update. Vision Marine Technologies, Inc. has filed a second patent for a cooling system con...

Vision Marine Innovates Electric Vessel Cooling System

Vision Marine files second patent for electric marine vessel cooling system control

Vision Marine Technologies, Inc. (VMAR) has released an update. Vision Marine Technologies, Inc. has announced the filing of a patent for a new coo...